Browse All

Current Filters

CLEAR FILTER x

TITLE

Author Institution:

Safety and Efficacy of Riliprubart, an Activated C1s-complement Inhibitor in CIDP: 76-week Phase Two Trial Results

Author:Querol, Luis   Lewis, Richard A.   Hartung, Hans-Peter   van Doorn, Pieter A.   Lin, Jie   Dionne, Annie   Attarian, Shahram   Wallstroem, Erik   Auwarter, Kristen   Lu, Yi   Alonso-Alonso, Miguel   Atassi, Nazem   Hughes, Richard A. C.   

Session Name:S2: Updates on Motor Neuron and Peripheral Nerve Disorders  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:S2.008  

Author Institution:Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain  Centro para la Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Madrid, Spain, Spain  Department of Neurology, Cedars Sinai Medical Center, Los Angeles, CA, USA, CA  Department of Neurology, Faculty of Medicine, Heinrich-Heine-University, Düsseldorf, Germany  Brain and Mind Center, University of Sydney, Sydney, NSW, Australia  Department of Neurology, Medical University of Vienna, Vienna, Austria  Department of Neurology, Palacky University Olomouc, Olomouc, The Czech Republic, Dusseldorf, Germany  Erasmus MC, University Medical Center, Rotterdam, The Netherlands, Netherlands  Department of Neurology and Rare Disease Center, Huashan Hospital, Fudan University, Shanghai, China, Shanghai, China, People's Republic of  CHU de Quebec Universite Laval, Quebec, Canada, QC, Canada  Neuromuscular Disease and ALS Reference Center, Timone University Hospital, Aix-Marseille University, CHU Timone, Marseille Cedex 05, France, France  Sanofi R&D, Neurology Development, Cambridge, MA, USA, Cambridge, MA  Sanofi, USA, MA  Sanofi R&D, Biostatistics and Programming, Cambridge, MA, USA, CA  Sanofi R&D, Neurology Development, Cambridge, MA, USA, MA  UCL Queen Square Institute of Neurology, University College London, London, UK, United Kingdom  

Fenfluramine in CDKL5 Deficiency Disorder: Primary Efficacy and Safety Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study

Author:Moseley, Brian   Specchio, Nicola   Marsh, Eric   Devinsky, Orrin   Aledo-Serrano, Ángel   Immacolata Battaglia, Domenica   Rajaraman, Rajsekar   Keough, Karen   Honda, Ryoko   Guerrini, Renzo   Melikishivili, Gia   Amin, Sam   Jaksha, Amanda   St. Wecker, Peter   Kilgallen, Brian   Dickson, Najla   Sullivan, Joseph   

Session Name:S5: Clinical Epilepsy  

Topic:Epilepsy/Clinical Neurophysiology (EEG)  

Program Number:S5.010  

Author Institution:UCB, Morrisville, NC  Bambino Gesù Children’s Hospital, IRCCS, Member of European Reference Network (ERN) EpiCARE  University Hospitals KU, Rome, Italy  Children's Hospital of Philadlephia  Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA  NYU Epilepsy Center, New York, NY  Neuroscience Institute, Vithas Madrid La Milagrosa University Hospital, Madrid, Spain  Fondazione Policlinico Universitario Agostino Gemelli, IRCCS  Università Cattolica del Sacro Cuore, Rome, Italy  David Geffen School of Medicine  UCLA Mattel Children’s Hospital, Los Angeles, CA  Child Neurology and Consultants of Austin, Austin, TX  Nagasaki Medical Center, Omura, Nagasaki, Japan  Meyer Children's Hospital IRCCS, Member of the ERN EpiCARE  University of Florence, Florence, Italy  MediClubGeorgia Medical Center, Tbilisi, Georgia  University Hospitals Bristol and Weston, Bristol, United Kingdom  Patient caregiver, Denver, CO  UCB, Emeryville, CA  Weill Institute for Neurosciences and Benioff Children’s Hospital, University of California San Francisco, San Francisco, CA